In Brief: FDA Biological Response Modifiers Advisory Committee
Executive Summary
FDA Biological Response Modifiers Advisory Committee: The committee will meet Nov. 13 to discuss Immunex' granulocyte macrophage colony stimulating factor Leukine (sargramostim) and Amgen's granulocyte colony stimulating factor Neupogen (filgrastim) for use in peripheral blood stem cell mobilization and transplantation in cancer treatment. The meeting will take place at FDA's Parklawn Building, conference rooms D & E, beginning at 8 a.m...